- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 1-A/A Offering statement
- PART II AND III Part II and III
- 11 Exhibit 11
- 13.1 Exhibit 13.1
- 13.2 Exhibit 13.2
- 13.3 Exhibit 13.3
- 13.4 Exhibit 13.4
- 13.5 Exhibit 13.5
- 13.6 Exhibit 13.6
- 13.7 Exhibit 13.7
- 13.8 Exhibit 13.8
- 13.9 Exhibit 13.9
- 13.10 Exhibit 13.10
- 13.11 Exhibit 13.11
- 13.12 Exhibit 13.12
- 13.13 Exhibit 13.13
- 13.14 Exhibit 13.14
- 19 Jan 22 253G2 Offering circular supplement
- 27 Dec 21 253G2 Offering circular supplement
- 1 Jun 21 253G2 Offering circular supplement
- 19 Jan 21 QUALIF Notice of qualification
- 7 Jan 21 1-A/A Offering $30M in Equity
- 23 Dec 20 1-A/A Offering $30M in Equity
-
4 Dec 20 1-A/A Offering $30M in Equity
- 13 Oct 20 1-A/A Offering $30M in Equity
- 30 Sep 20 1-A/A Offering $30M in Equity
- 28 Aug 20 1-A Offering $30M in Equity
Exhibit 13.13
Advertisement: Monogram This Is Monogram 30 sec RESERVE_SE
Duration: 30 Seconds
CTA: startengine.com/monogram
Tagline: “Reserve”
Narrator: “This is Monogram. We are an Austin, Texas*-based medical technology company transforming the orthopedic market by combining state-of-the-art surgical robotics with patient optimized implant design.”
Sherif Aly, PhD, VP of Engineering: “What’s really unique is the software that controls the arm. Because that, someone would have to develop from scratch.”
Dr. Douglas Unis, Founder & CMO: “This is the future of orthopedics, and it is inevitable.”
Narrator: “A unique opportunity awaits. To learn more and reserve your shares visit startengine.com/monogram, that’s startengine.com/monogram.”
* Testing the waters disclaimer